Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies
ConclusionWhile there was a trend toward improved HR control with IV diltiazem compared with IV metoprolol in randomized trials, this was not seen in observational studies, and there was no observed difference in hypotension between the two drugs. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - October 19, 2023 Category: Cardiology Source Type: research
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non- β-Blocking R-Enantiomer Carvedilol
CONCLUSIONS: R-enantiomer carvedilol attenuates hyperdynamic contraction, suppresses arrhythmia, and at the same time, improves cardiac output without lowering heart rate by dual blockade of α1-adrenergic receptor and RyR2 in mouse and human models of HCM. This combination of therapeutic effects is unique among current therapeutic options for HCM and may particularly benefit patients without LV outflow tract obstruction.PMID:37850394 | DOI:10.1161/CIRCULATIONAHA.123.065017 (Source: Circulation)
Source: Circulation - October 18, 2023 Category: Cardiology Authors: Kinya Seo Yuta Yamamoto Anna Kirillova Masataka Kawana Sunil Yadav Yong Huang Qianru Wang Kerry V Lane Beth L Pruitt Marco V Perez Daniel Bernstein Joseph C Wu Matthew T Wheeler Victoria N Parikh Euan A Ashley Source Type: research
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non- β-Blocking R-Enantiomer Carvedilol
CONCLUSIONS: R-enantiomer carvedilol attenuates hyperdynamic contraction, suppresses arrhythmia, and at the same time, improves cardiac output without lowering heart rate by dual blockade of α1-adrenergic receptor and RyR2 in mouse and human models of HCM. This combination of therapeutic effects is unique among current therapeutic options for HCM and may particularly benefit patients without LV outflow tract obstruction.PMID:37850394 | DOI:10.1161/CIRCULATIONAHA.123.065017 (Source: Circulation)
Source: Circulation - October 18, 2023 Category: Cardiology Authors: Kinya Seo Yuta Yamamoto Anna Kirillova Masataka Kawana Sunil Yadav Yong Huang Qianru Wang Kerry V Lane Beth L Pruitt Marco V Perez Daniel Bernstein Joseph C Wu Matthew T Wheeler Victoria N Parikh Euan A Ashley Source Type: research
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
ConclusionRelugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.Trial RegistrationClinical Trial ID NCT03085095.Prior Presentation Data presented at 15th Annual Genitourinary Cancers Symposium; February 17 –19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found athttps://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101. (Source: Advances in Therapy)
Source: Advances in Therapy - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
Ann Med Surg (Lond). 2023 Sep 1;85(10):4989-5000. doi: 10.1097/MS9.0000000000001244. eCollection 2023 Oct.ABSTRACTBACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have not been systematically evaluated by economics. The purpose of this study was to assess the efficacy, safety, and economy of the SSYX in the treatment of arrhythmia in patients with coronary heart disease.METHODS: W...
Source: Annals of Medicine - October 9, 2023 Category: Internal Medicine Authors: Luyao Ma Libing Li Fujin Ma Fuyun Ma Shujia Ma Source Type: research
β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention
CONCLUSION: β1-blockers might be beneficial for the reduction of bleeding risk in potent dual antiplatelet therapy patients with ACS or undergoing PCI.PMID:37783287 | DOI:10.1016/j.hjc.2023.09.017 (Source: Hellenic Journal of Cardiology)
Source: Hellenic Journal of Cardiology - October 2, 2023 Category: Cardiology Authors: Shizhao Zhang Yangxun Wu Chao Lv Haiping Liu Yuyan Wang Lisha Dong Yuqi Liu Shengshu Wang Jianjun Jia Tong Yin Source Type: research
The influence of metoprolol in patients with sepsis-induced cardiomyopathy: A retrospective study
CONCLUSION: Metoprolol can reduce the 28-day mortality and shorten the duration of mechanical ventilation in SICM. It can also reduce the number of organ failures and improve the oxygenation index and Glasgow coma scale of these patients. Meanwhile, metoprolol did not affect the norepinephrine dose in patients with SICM.PMID:37777259 | DOI:10.15537/smj.2023.44.10.20230149 (Source: Saudi Medical Journal)
Source: Saudi Medical Journal - September 30, 2023 Category: Middle East Health Authors: Wenna Ning Yaou Chen Jian Lu Jinwei Zhu Longgang Li Source Type: research
